Collegium Pharmaceutical, Inc. COLL Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 59.3%-0.4pp | 59.8%+2.2pp | 57.5%+12.4pp | 45.2%-9.2pp | |
| Operating margin | 23%-3.9pp | 26.9%-2.6pp | 29.5%+22.3pp | 7.2%+0.8pp | |
| Net margin | 8.1%-2.9pp | 11%+2.5pp | 8.5%+13.9pp | -5.4%-31.2pp | |
| Returns | |||||
| Return on equity | 23.7%-8.9pp | 32.6%+7.9pp | 24.7%+37.2pp | -12.6%-49.3pp | |
| Return on invested capital | 125.6%— | —— | —— | 121.9%+46.4pp | |
| Efficiency | |||||
| Asset turnover | 0.5×0.0× | 0.4×0.0× | 0.5×0.0× | 0.5×+0.1× | |
| Liquidity | |||||
| Current ratio | 1.6×+0.6× | 0.9×-0.2× | 1.2×+0.2× | 1×-0.2× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Net debt / EBITDA | -1×-0.8× | -0.3×+0.5× | -0.7×+0.5× | -1.3×+0.8× | |
| Per Share | |||||
| Book value per share | $7.53+31.9% | $5.71+20.5% | $4.73-18.4% | $5.80-2.4% | |
| Valuation | |||||
| Market capitalization | $1.15B+20.4% | $923.97M-7.9% | $1B+28.9% | $778.87M+20.6% | |
| Price / earnings | 15.4×-6.4× | 13.4×-7.5× | 20.8×— | —— | |
| Price / sales | 1.5×0.0× | 1.5×-0.3× | 1.8×+0.1× | 1.7×-0.7× | |
| Price / book | 3.7×-0.4× | 4×-1.1× | 5.1×+1.1× | 4×+0.8× | |
| EV / EBITDA | 3.5×+1.0× | 2.5×0.0× | 2.4×-2.3× | 4.7×-0.7× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Collegium Pharmaceutical, Inc.'s profit margins?
- Collegium Pharmaceutical, Inc. (COLL) runs a 60.7% gross margin and a 23.7% operating margin, with a 9.4% net margin.
- Where do Collegium Pharmaceutical, Inc.'s ratios come from?
- Every ratio is computed from Collegium Pharmaceutical, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
